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Activation of trace amine-associated receptor 1 (TAAR1) in endocrine pancreas is
involved in weight regulation and glucose homeostasis. The purpose of this study
was the identification and characterization of potential TAAR1 variants in patients with
overweight/obesity and disturbed glucose homeostasis. Screening for TAAR1 variants
was performed in 314 obese or overweight patients with impaired insulin secretion.
The detected variants were functionally characterized concerning TAAR1 cell surface
expression and signaling properties and their allele frequencies were determined in the
population-based Study of Health in Pomerania (SHIP). Three heterozygous carriers of
the single nucleotide missense variants p.Arg23Cys (R23C, rs8192618), p.Ser49Leu
(S49L, rs140960896), and p.Ille171Leu (I171L, rs200795344) were detected in the
patient cohort. While p.Ser49Leu and p.Ille171Leu were found in obese/overweight
patients with slightly impaired glucose homeostasis, p.Arg23Cys was identified in a
patient with a complete loss of insulin production. Functional in vitro characterization
revealed a like wild-type function for I171L, partial loss of function for S49L and
a complete loss of function for R23C. The frequency of the R23C variant in 2018
non-diabetic control individuals aged 60 years and older in the general population-
based SHIP cohort was lower than in the analyzed patient sample. Both variants are
rare in the general population indicating a recent origin in the general gene pool and/or
the consequence of pronounced purifying selection, in line with the obvious detrimental
effect of the mutations. In conclusion, our study provides hints for the existence of
naturally occurring TAAR1 variants with potential relevance for weight regulation and
glucose homeostasis.
Keywords: trace amine-associated receptor 1, variants, weight regulation, glucose homeostasis, signal
transduction
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INTRODUCTION
The G protein coupled receptor (GPCR) trace amine associated
receptor 1 (TAAR1) is activated by biogenic trace amines
such as beta-phenylethyl amine (PEA) and tyramine or
octopamine (Borowsky et al., 2001; Lindemann and Hoener,
2005). In addition to trace amines, 3-iodothyronamine (T1AM),
a molecule with structural similarity to thyroid hormones,
is a ligand for rodent and human TAAR1 (Scanlan et al.,
2004; Kleinau et al., 2011). So far, no physiological function
for the T1AM/TAAR1 complex in humans was described.
TAAR1 signals via the Gs/adenylyl cyclase system by enhancing
intracellular cAMP after ligand challenge.
In pancreatic beta-cells, TAAR1 activation by T1AM enhances
insulin secretion (Regard et al., 2007). By using a TAAR1-specific
artificial agonist RO5166017 (Revel et al., 2011), the role of
TAAR1 in controlling food intake and glucose homeostasis was
recently further delineated (Raab et al., 2016). Insulin secretion
from a pancreatic beta-cell line and human pancreatic islets could
be stimulated under high glucose concentrations (Raab et al.,
2016) and treatment of diet-induced obese mice with RO5166017
resulted in reduction of food intake and body weight (Raab et al.,
2016). Furthermore, TAAR1 was found to be highly expressed
in pancreatic islets (Regard et al., 2007; Raab et al., 2016), the
stomach, and gut (Ito et al., 2009; Revel et al., 2013; Raab et al.,
2016).
The relevance of TAAR1 action in human endocrine pancreas
physiology needs to be determined since no associations between
TAAR1 variants and obesity or diabetes have been reported
to date. Of note, it was recently demonstrated that single
nucleotide polymorphisms (SNPs) in human TAAR1 may alter its
properties, resulting in expressed, but functional, sub-functional
and non-functional receptors, which is of importance for
identifying predispositions to human diseases (Shi et al., 2016).
In this present study, 314 patients with different levels of
impaired glucose homeostasis were screened for TAAR1 variants.
Our data support a potential role of the TAAR1 in glucose
homeostasis and body weight regulation in which TAAR1
variants may predispose to disturbances in maintaining intact
insulin secretion.
MATERIALS AND METHODS
Description of the Patient Cohort
Screening for mutations was performed in a group of 314 patients
from the Charité Pediatric Diabetes and Obesity outpatient
clinic. Of these, 94 patients suffered from antibody-negative
diabetes with onset before the age of 18 years and did not
have mutations in genes causing monogenic diabetes (GCK,
HNF4A, HNF1A, HNF1B, ABCC8, KCNJ11, INS). The remaining
220 patients were overweight or obese and exhibited impaired
glucose homeostasis. Overweight was defined as >90. percentile
and obesity >97. percentile according to German references
(Kromeyer-Hauschild et al., 2001). Impaired glucose homeostasis
was diagnosed by an increased insulin resistance in a fasting
state, determined by elevated HOMA-IR (homeostatic model
assessment in insulin resistance) or by an impaired oral glucose
tolerance test.
Description of the Population-Based
Control Cohort
The variant frequencies of p.ArgR23Cys (rs8192618) and
p.Ser49Leu (rs140960896) were determined for 2,018 diabetes-
free participants older than 60 years of age from the population-
based SHIP and SHIP-TREND cohorts. Individuals were
classified as diabetics if they were diagnosed accordingly (type I
or II) by a physician (self-reported during an interview), were
under anti-diabetic medication (ATC-code A10), or exhibited
increased blood or serum glucose levels (HbA1c ≥ 6.5 and
% ≥ 11.1 mmol/l, respectively). All other individuals were
classified as diabetes-free.
Study of Health in Pomerania is a population-based project
in West Pomerania, a region in the northeast of Germany,
that consists of two independent prospectively collected cohorts
(SHIP and SHIP-TREND) assessing the prevalence and incidence
of common population-based diseases and their risk factors. The
study design has been previously described in detail (Volzke et al.,
2011).
For SHIP, baseline examinations were carried out from
1997 until 2001, and the sample finally comprised 4,308
participants. Baseline examinations for SHIP-TREND were
carried out between 2008 and 2012 and comprised a total of 4420
participants.
Genotyping of the SHIP and
SHIP-TREND Cohorts
The SHIP and SHIP-TREND samples were genotyped using the
Illumina ExomeChip array (version Infinium HumanExome v1.0
DNA Analysis BeadChip). Array processing was performed in
accordance with the manufacturer’s standard recommendations
at the Helmholtz Zentrum München. Genotype calling was
performed according to the ExomeChip quality control
SOP version 5. Initial genotypes were determined using
the GenomeStudio Genotyping Module v1.0 (GenCall
algorithm) with the HumanExome-12v1_A manifest file
and the standard Illumina cluster file (HumanExome-12v1.egt).
Contaminated samples, samples with a call rate < 90%,
extreme heterozygosity, extensive estimated IBD sharing with
a large number of samples, or mismatch between reported
and genotyped sex were excluded. Next, missing genotypes
were recalled with the zCall software version 3.3 using
default values. In both cohorts, a total of 8,177 individuals
were successfully genotyped with an average call rate of
99.97%.
Variant Screening and Cloning of TAAR1
Wild-Type and Receptor Variants
PCR amplification of the TAAR1 gene was performed by using
the following primer pairs: forward tttcctcctaggtttctggga and
reverse tccaccactgaacagctgac, located in the 5′ and 3′ region of
the gene and giving rise to a 1457 bp long PCR fragment. Variant
screening was performed by using the amplification primer and
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two additional primers (CTGGAGCTAAACTTCAAAGG and
CTTGCCTGTTCTTTAGCGAT, located in the coding region
of the gene) to cover the whole region in both directions
using. For sequencing BigDye terminator (PerkinElmer Inc.,
Waltham, MA, United States) automatic sequencing (ABI3710xl,
Applied Biosystems, Foster City, CA, United States) of the coding
region of TAAR1 (NP_612200.1, NM_138327.2) was applied.
TAAR1 wild-type (TAAR1-WT) was cloned in the eukaryotic
expression vector pcDps as previously described (Kleinau et al.,
2011).
The three single nucleotide variants identified by patient
screening, p.Arg23Cys (R23C), p.Ser49Leu (S49L), and
p.Ille171Leu (I171L), were introduced into TAAR1 using site-
directed mutagenesis according to manufacturer’s instructions
of Pfu turbo DNA polymerase (Stratagene, La Jolla, CA,
United States).
To enhance cell surface expression for functional analysis,
TAAR1 was N-terminally fused with the first 20 amino acids of
the bovine rhodopsin (Rho-tag) as previously described (Dinter
et al., 2015).
For surface ELISA (enzyme-linked immunosorbent
assay), receptor constructs were N-terminally tagged with a
hemagglutinin epitope (HA, 5′ YPYDVPDYA 3′) (previous to
the Rho-tag).
For SNAP-tag technology, TAAR1-WT and variants were
subcloned into the N-terminally SNAP-tagged pcDNA5
vector (New England Biolabs GmbH, Frankfurt am Main,
Germany).
Cell Culture and Transfection
For cAMP assay and SNAP-tag experiments, HEK293 cells
were cultured in Minimum Essential Media (MEM) and for
cell surface ELISA, COS-7 cells were cultured in Dulbecco’s
Modified Eagle Medium (DMEM) (both Biochrom AG, Berlin,
Germany), at 37◦C and 5% CO2. MEM was supplemented
with 5% FBS and non-essential amino acids (Biochrom AG,
Berlin, Germany). DMEM was supplemented with 5% FBS
and 100 U/ml penicillin, 100 µg/ml streptomycin (Biochrom
AG, Berlin, Germany), and 2 mM L-glutamine (Invitrogen,
Carlsbad, CA, United States). We used two different cell
lines because HEK293 cells are an established cell system
for investigation of GPCR structure-function relationships.
However, for methods that involve intensive washing, like the
sandwich ELISA approach, a more robust cell line like COS-7
cells is appropriate.
Transient transfection was carried out using Metafectene
(Biontex, Munich, Germany) for cAMP Assay and surface
ELISA or FuGene6 (Promega, Fitchburg, WI, United States)
for SNAP-tag experiments according to the manufacturers’
protocol.
Cell Surface Expression Using SNAP-Tag
Technology and ELISA
For determination of cell surface expression with fluorescent-
based SNAP-tag technology, cells expressing TAAR1-WT and
mutant receptor constructs were fixed with 4% PFA and 200 mM
HEPES followed by staining with the photostable fluorescent
SNAP-Surface R© Alexa Fluor R© 488 (1:1,000 diluted in Advanced
MEM (New England Biolabs GmbH, Frankfurt am Main,
Germany), which covalently binds to the SNAP-tag (Cole, 2013).
For SNAP-tag technology nuclei were stained using DAPI
dye (Life Technologies, Darmstadt, Germany). Microscopy was
performed using an inverted light microscope Axiovert 10
(Carl Zeiss Microscopy GmbH, Oberkochen, Germany) at 63x
magnification. Additionally, for verification and quantification
of results, a surface ELISA was performed. Therefore, COS-7
cells were transiently transfected with the HA-tagged TAAR1
constructs and empty vector (mock, negative control).
For cell surface expression, cells were fixed with 4%
paraformaldehyde and blocked with 10% FBS overnight 48 h
after transfection, Next, cells were incubated with biotin-labeled
anti-HA antibody (Roche, Basel, Switzerland) (1:200). Bound
antibodies were detected with horseradish peroxidase-labeled
Streptavidin (BioLegend, London, United Kingdom) (1:2,500).
Color reaction was performed as described (Muhlhaus et al.,
2014) and absorption was measured at 492 nm and 620 nm using
an Anthos Reader 2001 (Anthos Labtech Instruments, Salzburg,
Austria).
Measurement of Gs Activation by cAMP
Accumulation Assay Based on
AlphaScreen Technology
HEK293 cells transiently expressing empty vector (mock),
TAAR1-WT, TAAR1-R23C, TAAR1-S49L, or TAAR1-I171L were
left untreated or were stimulated with increasing concentrations
of T1AM (from 1 nM to 10 µM) (Santa Cruz Biotechnology Inc.,
Dallas, TX, United States) or β-phenylethylamine (PEA) 10 µM
in the presence of isobuthylmethylxanthine (IBMX). After cell
lysis, cAMP levels were measured using AlphaScreen Technology
(Perkin-Elmer Life Science, Boston, MA, United States) (Kleinau
et al., 2011).
Statistical Analysis
Statistical analyses were performed using the R statistical software
version 2.15.31 and GraphPad Prism 6.0. One-way ANOVA was
performed for the effect of TAAR1 stimulation by T1AM or PEA
and for cell surface expression.
Molecular Homology Modeling of TAAR1
in an Inactive State Conformation
The details of structural TAAR1 homology modeling were
described previously (Kleinau et al., 2011). In brief, the already
determined structure of the β-adrenergic receptor 2 (pdb entry
2RH1, Cherezov et al., 2007) was used as a structural template
for TAAR1 modeling in an inactive state, based on high sequence
similarity between hTAAR1 and the β-adrenergic receptor 2.
The loops were manually adjusted in length and amino acid
composition. The ligand bound to the template was deleted.
For all modeling procedures, the software package Sybyl 8.0
(Certara, NJ, United States) was used. Substituted side chains and
1www.R-project.org
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FIGURE 1 | Cell surface expression visualized with fluorescence-based SNAP-tag technology. For fluorescence-based determination of cell surface expression,
HEK293 cells expressing empty vector (mock), TAAR1-WT or mutant receptor constructs (R23C, S49L, I171L) were stained with the photostable fluorescent
SNAP-Surface R© Alexa Fluor R© 488 (green). Nuclei were DAPI-stained (blue). Microscopy was carried out with an inverted light microscope Axiovert 10 at 63x
magnification. (A) mock-transfected cells; (B) TAAR1-WT; (C) TAAR1-R23C; (D) TAAR1-S49L; (E) TAAR1-I171L.
loops were subjected to molecular dynamics simulation (4 ns)
by fixing the backbone of the transmembrane helices, followed
by conjugate gradient minimizations until converging at a
termination gradient of 0.05 kcal/(mol∗Å). The AMBER 7.0 force
field was used. Structure images were produced using PyMOL
Molecular Graphics System, version 1.5, Schrödinger, LLC.
RESULTS
Three Heterozygous TAAR1 Single
Nucleotide Variants in Patients with
Impaired Glucose Tolerance
Screening of 314 patients with impaired glucose tolerance
revealed three heterozygous carriers of single nucleotide
variants in the TAAR1 coding region: p.Arg23Cys (R23C,
rs8192618), p.Ser49Leu (S49L, rs140960896), and p.Ile171Leu
(I171L, rs200795344). This corresponds to a minor allele
frequency (MAF) of 0.16% for each variant in this patient
sample.
Identified TAAR1 Variants Are Properly
Expressed at the Cell Surface
Two different methods were used to investigate cell surface
localization of TAAR1. The SNAP technology revealed TAAR1
wild-type (TAAR1-WT) and variants in intact cells (Figure 1),
whereas the cell surface ELISA allowed for the quantification of
cell surface expression (Figure 2A). Using both methods, cell
surface localization of all three mutated TAAR1 proteins was
statistically not different to wild-type.
Specific TAAR1 Variants Are Reduced in
Signaling Properties
Wild-type TAAR1 and the three TAAR1 mutant proteins
were expressed in HEK293 cells and T1AM-induced cAMP
accumulation was measured. Compared with wild-type TAAR1
(EC50: 2.8 µM), the R23C variant demonstrated a complete loss
of function in cAMP accumulation (significant, p≤ 0.001), which
did not allow for a proper EC50 calculation. Maximal stimulation
for S49L and I171L was reduced to 60% (significant, p≤ 0.05) and
80% (not significant) compared with the wild-type, respectively
(Figure 3A).
To mimic the heterozygous genotype of the patients,
co-transfection studies of wild-type (WT) and mutant receptors
were performed. For determination of whether cell surface
localization of the WT receptor is influenced by the mutated
receptors, cells were co-transfected with Flag-tagged TAAR1-WT
and HA-tagged TAAR1 variants. While cell surface localization
was not impaired for all three variants (Figure 2B), R23C
and S49L co-expression with TAAR1-WT significantly reduced
maximal Gs signaling to 58% (significant, p ≤ 0.05), and
55% (significant, p ≤ 0.05) of WT + empty vector signaling,
respectively (Figure 3B), indicating a dominant-negative effect.
In contrast, signaling of the TAAR1 I177L variant+ TAAR1-WT
was not affected. Furthermore, the S49L variant resulted
in a slight shift toward higher EC50 values (0.7 µM for
TAAR1 + empty vector and 1.9 µM for wild-type + S49L)
(Figure 3B).
Beta-phenylethylamine (PEA) is known to be one of the
most potent ligands for TAAR1 (Wainscott et al., 2007).
For determination of Gs signaling properties after stimulation
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FIGURE 2 | TAAR1 variants show surface expression comparable to TAAR1 wild-type. Cell surface expression of TAAR1 wild-type (TAAR1-WT) and TAAR1 variants
was determined via ELISA in COS-7 cells. TAAR1-WT-Flag or empty vector (mock) served as a negative control. Data are depicted as mean ± SEM of relative cell
surface expression (OD 492 nm/620 nm) based on three independent experiments performed in four replicates. (A) Cells were transiently transfected with
HA-tagged TAAR1-WT, TAAR1-R23C, TAAR1-S49L, and TAAR1-I171L. (B) For determination of whether cell surface expression of the wild-type receptor is
influenced by the mutated receptors, cells were co-transfected with Flag-tagged TAAR1 wild-type and HA-tagged TAAR1-varaints. Statistical analysis was
performed using a one-way ANOVA with Kruskal–Wallis test. TAAR1-WT was tested against variants for (A) and TAAR1-WT + TAAR1-WT against
variants + TAAR1-WT for (B). For (A,B) no statistical significant difference was observed.
with PEA, HEK293 cells transiently transfected with TAAR1
wild-type (TAAR1-WT) and TAAR1 variants were stimulated
with 10−5M PEA and cAMP accumulation was measured.
The R23C mutant showed a complete loss of function
indicated by non-responsiveness to PEA (significant, p ≤ 0.001)
(Figure 4). The Gs/adenylyl cyclase-mediated signaling of the
S49L variant demonstrated a significant signal reduction of
approximately 70%, (p ≤ 0.001) while the I171L substitution
exhibited only a slight, but not significant, reduction of cAMP
accumulation.
In summary, R23C represented a complete loss-of-function
variant, S49L a partial loss-of-function variant, and despite a
slightly reduced maximal signaling capacity, I171L was classified
as WT-like and excluded from further analysis.
Patient Phenotypes
Patient 1 (variant p.Arg23Cys carrier) was born small for
gestational age to non-related parents of Middle Eastern
background. He developed insulin-dependent diabetes at 3 years
of age with low C-peptide, and negative anti-GAD and
anti-insulin antibodies. Further evaluation did not reveal variants
in known monogenic diabetes genes. At 7 years of age, his mental
performance was tested and revealed an IQ of 71. Additionally,
his growth rate consistently decreased and at 6 years of age,
he was tested for growth hormone deficiency with normal MRI
findings of the brain and pituitary gland. His father (non-carrier
of a variant) developed type 2 diabetes at 40 years of age and
was not obese. Treatment was comprised of oral antidiabetic
drugs. The mother is a heterozygous variant carrier and is
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normoglycemic. Thyroid hormone levels were in the reference
range.
Patient 2 (variant p.Ile171Leu carrier) was diagnosed at 11
4/12 years of age with obesity (BMI, 30.0 kg/m2;+2.59 BMI-SDS)
and a disturbed glucose homeostasis (HOMA-IR, 2.8) and
transient pathological oral glucose tolerance test. There was no
family background of type 2 diabetes or cardiovascular problems.
Lifestyle intervention resulted in weight loss (BMI, 25.5 kg/m2)
and HOMA-IR values normalized but were not completely stable
(0.7–1.7). Thyroid function was normal.
Patient 3 (variant p.Ser49Leu carrier) was overweight (BMI
25.0 kg/m2) and had a disturbed glucose homeostasis (IGT;
HOMA-IR, 2.9). Lifestyle intervention resulted in weight loss
and normalization of HOMA-IR; however, the patient regained
weight (BMI, 29.0 kg/m2) and HOMA-IR increased to 6.
There was no reported family history of type 2 diabetes or
cardiovascular complications. Thyroid function was normal.
The patient discontinued from the treatment group because of
psychiatric problems.
Samples from the parents of patients 2 and 3 were
unavailable.
Variant Frequencies in a Large Control
Population
The results so far suggest that two of the three single
nucleotide variants, namely p.Arg23Cys (rs8192618) and
p.Ser49Leu (rs140960896), might predispose to impaired
glucose homeostasis. The design of a proper control cohort to
detect putative enrichment of these variants in patients had to
anticipate a variable and mild manifestation of the phenotype
with increasing age. Therefore, participants of the SHIP study
that were ≥60 years of age and diabetes-free were assigned to
this control group, thereby increasing the likelihood of including
unaffected individuals. Within the SHIP and SHIP-TREND
cohorts, 2,018 individuals that were ≥60 years of age were
diagnosed as diabetes-free (see description of the control
population) and were subsequently analyzed for the p.Arg23Cys
(rs8192618, genotyping data for 2,009 individuals available) and
p.Ser49Leu (rs140960896, genotyping data for 2,018 individuals
available) allele frequencies. In this control group, only nine
individuals were found to be heterozygous carriers of p.Ser49Leu,
while no carriers were observed for p.Arg23Cys (Table 1). In
the remaining SHIP sample, patients with <60 years of age that
included individuals with the potential of developing diabetes
at an older age, the number of heterozygous p.Ser49Leu carriers
amounted to 18 of 5,149 individuals with available genotyping
data. Four heterozygous p.Arg23Cys carriers were found among
the 5,163 individuals with the available genotyping data. The
corresponding single nucleotide variant minor allele frequencies
(MAFs) for the older control cohort, the younger remaining
cohort, and the total SHIP study were 0.00%, 0.04%, and 0.03%
for p.Arg23Cys (rs8192618), respectively, and 0.22%, 0.17%, and
0.19% for p.Ser49Leu (rs140960896), respectively. The MAFs
reported for the aggregated general population (121,408 samples
from the dbSNP database2) amount to 0.154 and 0.038% for
p.Arg23Cys and p.Ser49Leu, respectively.
DISCUSSION
Recently, a physiological role for TAAR1 in glucose homeostasis
and food intake in rodents was reported (Raab et al., 2016). Due
to the generation of a new monoclonal antibody, the expression
spectrum of human TAAR1 was reported in endocrine organs
that are capable of secreting hormonal signals involved in energy
metabolism such as the pancreas, stomach, and gut (Raab et al.,
2016). Of specific note, stimulation of a rat pancreatic islet cell
line or human isolated pancreatic islets with the TAAR1 specific
agonist RO5166017 led to an increase in insulin secretion and
application of RO5166017 to diet-induced obese mice reduced
food intake and body weight (Raab et al., 2016). Yet, the
2http://www.ncbi.nlm.nih.gov/projects/SNP/
TABLE 1 | Genotype frequencies of the TAAR1 variants p.Arg23Cys and p.Ser49Leu of diabetes-free individuals from the population-based SHIP-cohort.
p.Ser49Leu (S49L, rs140960896) p.Arg23Cys (R23C, rs8192618)
Age group (years) [n] Non-carriers [n] Heterozygote A alleles [n] MAF (%) Non-carriers [n] Heterozygote A alleles [n] MAF (%)
20–29 889 2 0.11% 890 1 0.06%
30–39 1,356 6 0.22% 1,361 1 0.04%
40–49 1,457 3 0.10% 1,459 1 0.03%
50–59 1,447 7 0.24% 1,453 1 0.03%
Total (younger) 5,149 18 0.17% 5,163 4 0.04%
60–69 1,207 5 0.21% 1,212 0 0.00%
70–79 738 4 0.27% 742 0 0.00%
80–83 64 0 0.00% 64 0 0.00%
Total (older) 2,009 9 0.22% 2,018 0 0.00%
Overall 7,158 27 0.19% 7,181 4 0.03%
The genotype frequencies of the single nucleotide variants p.Arg23Cys (R23C, rs8192618) and p.Ser49Leu (S49L, rs140960896) are shown for 5,167 diabetes-free SHIP
and SHIP-TREND participants aged younger than 60 years of age (upper part) and 2,018 individuals aged 60 years and older (lower part). MAF, minor allele frequency.
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FIGURE 3 | Gs signaling properties of TAAR1 wild-type and TAAR1 variants
R23C, S49L, and I171L after stimulation with T1AM. For determination of Gs
signaling properties, HEK293 cells, transiently transfected with TAAR1
wild-type (TAAR1-WT) and TAAR1 variants, were stimulated with T1AM
(10−9M – 10−5M) and cAMP accumulation was measured with the
AlphaScreen technology. Cells transfected with empty vector (mock) served
as a negative control. Data are represented as mean ± SEM of fold over basal
of the respective receptor variant and are based on 5–7 independent
experiments performed in triplicates. Significance was calculated using
one-way ANOVA; ∗p ≤ 0.05, ∗∗∗p ≤ 0.001. To mimic the (A) homozygous
state and the (B) heterozygous state, cells were transfected with TAAR1-WT,
TAAR1-R23C, TAAR1-S49L, or TAAR1-I171L.
FIGURE 4 | Gs signaling properties of TAAR1 wild-type and TAAR1 variants
after stimulation with PEA. TAAR1 wild-type (TAAR1-WT) and TAAR1 variants
were stimulated with 10−5M agonist beta-phenethylamine (PEA) and cAMP
accumulation was measured with the AlphaScreen technology. Cells
transfected with empty vector (mock) served as a negative control. Data are
represented as mean ± SEM of fold over the basal of the respective receptor
variant and are based on four independent experiments performed in
triplicates. Significance was calculated using one-way ANOVA; ∗∗∗p ≤ 0.001.
pathophysiological role of TAAR1 action in humans remains
elusive. In the present study, we screened for TAAR1 variants in
a cohort of patients that were overweight/obese with disturbed
glucose homeostasis and in patients with a lack of appropriate
insulin secretion. Several genes are known to cause monogenic
obesity (Farooqi and O’Rahilly, 2008) and diabetes (Henzen,
2012); however, variations in the genes of polygenic obesity also
add to the complex clinical spectrum (Hinney et al., 2010; van der
Klaauw and Farooqi, 2015).
Two TAAR1 variants, namely, p.Arg23Cys (rs8192618) and
p.Ser49Leu (rs140960896), were identified in the currently
investigated patient sample. Data from the population-based
SHIP study were used to determine the frequencies of these
variants in control individuals recruited from the general
adult population. To optimize the control cohort to comprise
of predominantly healthy individuals, we assigned diabetes-
free SHIP participants aged 60 years and older to this
group. In contrast to the patient sample, no carrier of the
p.Arg23Cys variant was observed in this cohort, while nine
heterozygous carriers of the p.Ser49Leu variant were found.
The fact that the frequency differences of the two variants
between the defined control cohort and the patient sample
did not show statistical significance is mainly explained by
the low frequencies of p.Arg23Cys and p.Ser49Leu in the
general population. Therefore, larger study samples would
be required to validate the observed associations with the
disease phenotypes. For example, data from approximately
700–1,000 patients are required to reveal a statistically significant
(P < 0.05) difference in the allele distribution between patients
and diabetes-free controls with an 80% power given to the
observed p.Arg23Cys minor allele frequency (MAF) of 0.03%
in the SHIP cohort. The other putative risk variant p.Ser49Leu
exhibited a MAF of 0.19% in the total analyzed SHIP cohort.
In the dbSNP database based on genotyping data of 121,408
samples, MAFs of 0.15, 0.04, and 0.02% were reported for
p.Arg23Cys, p.Ser49Leu and p.Ile171Leu, respectively. In spite
of these MAF differences, the two variants in any case belong
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FIGURE 5 | Identified TAAR1 sequence variations mapped to a three-dimensional TAAR1 model in an inactive conformation. (A) This sequence alignment shows
overlapping or diverse amino acids at corresponding positions between several TAAR1 orthologous and additionally compared to other human TAAR group
members (alignment is performed manually; the alignment was visualized with the software BioEdit.). The positions of the here investigated sequence variants are
indicated by arrows. Particular background colors, indicating conservation (Blossum62 matrix) among different receptors and simultaneously reflecting biophysical
properties of the amino acid side chains: black – proline, blue – positively charged, cyan/green – aromatic and hydrophobic, green – hydrophobic, red – negatively
charged, gray – hydrophilic, dark-red – cysteines, magenta – histidine. (B) The 3-dimensional hTAAR1 model shows the spatial localization of the wild-type amino
acids (colored sticks, labeled) at the positions of identified substitutions. The model is based on a previously described modeling approach (Kleinau et al., 2011).
Arginine 23 is located at the transition between transmembrane helix 1 (TM1) and the N-terminal tail (Ntt) at the extracellular side. The side chain of Arg23 can
potentially interact with residues of the extracellular loop 1 (ECL1) such as the negatively charged Glu86 or with the Asp21 located in the N-terminal tail (Ntt). The
amino acid Arg23 is conserved among TAAR1 orthologous (two variants Qln, His). In contrast, Ser49 points to the cytosol at the transition between TM1 and the
intracellular loop 1 (ICL1). This residue is highly conserved throughout TAAR1 orthologs (see A) and may be involved in the maintenance of structural conformation in
this specific receptor part, whereby a direct contact partner cannot be observed in our model. Isoleucine at position 171 is located in the putative helical extracellular
loop 2 (ECL2) structure and the side chain is close to hydrophobic side chains of amino acids like Ala168 or Phe165.
to the category of low frequency variants (MAF ≤ 0.5%)
(The 1000 Genomes Project Consortium, 2015), indicating
their recent origin in the general gene pool and/or the
consequence of pronounced purifying selection, in line with
the predicted detrimental effect of the resulting amino acid
exchanges.
Recently, a screen for TAAR1 variants in patients suffering
from schizophrenia was performed. In this study they identified
the variant p.Cys182Phe in three affected members of a family.
Prediction tools indicated that this variant might be of functional
relevance. In addition, by screening more patients the authors
identified six additional variants of which probably four were of
functional relevance (John et al., 2017). Here functional studies
may provide additional evidence if these variants are associated
with the phenotype of the patients.
In our study, functional TAAR1 characterization, including
determination of cell surface localization and signaling properties
(Gs), revealed a complete loss of function for the R23C
variant. While the heterozygous variant carrier lacked insulin
secretion, his mother exhibited normal Hb1C levels in spite
of the same genotype. The father of the patient was not
a TAAR1 variant carrier; however, he suffered from type
2 diabetes of unknown origin. Therefore, in addition to
the maternally inherited p.Arg23Cys variant, at least one
additional (unknown) diabetes-predisposing variant may have
been potentially inherited from the father accounting for the
patient’s phenotype. Such an effect was already demonstrated for
variants involved in congenital hypothyroidism (Sriphrapradang
et al., 2011).
Interestingly, functional characterization of S49L, especially in
the heterozygous state, decreases TAAR1 signaling induced by
T1AM or PEA (Figures 3A, 4). Consistently, the corresponding
patient was found to be greatly affected compared with the patient
carrying the I171L variant.
The arginine residue at position 23 of TAAR1 is located at
the transition between transmembrane helix 1 (TM1) and the
N-terminal tail (Ntt) at the extracellular side of the receptor
(Figure 5). The side chain of Arg23 may interact with residues
of the extracellular loop 1 such as the negatively charged Glu86
or the Asp21 at the N-terminus. Both amino acids are conserved
among TAAR1 orthologous, whereby Glu86 - in contrast to
Asp21- is also conserved among different human TAAR subtypes,
which supposes in combination with the high conservation of
Arg23 an interaction between these two residues. In contrast,
serine 49 points to the cytosol at the transition between TM1
and the intracellular loop 1. This residue is highly conserved
throughout TAAR1 orthologous (but not in the TAAR group)
and may be involved in the maintenance of the structural
conformation in this specific receptor section by a H-bond to the
helical backbone. Modifications at this position should therefore
lead to decreased capacity of the receptor to interact with the
G-protein.
In summary, we identified TAAR1 variants in a patient
cohort affected by overweight/obesity and disturbed glucose
homeostasis. Functional characterization of the corresponding
protein variants revealed substantial effects of R23C and S49L
on receptor signaling. We observed only a trend toward a higher
frequency of these variants in our patient cohort compared with
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a population-based control sample, which, however, may be
explained by a lack of power due to the low frequencies of the
variants in the general population. Therefore, additional studies
in larger cohorts are necessary to further unravel the complete
potential of TAAR1 in human beta-cell function. So far, we
conclude that TAAR1 variants may represent at least low frequent
modifiers of insulin secretion, glucose homeostasis, and weight
regulation.
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